229 related articles for article (PubMed ID: 15843558)
1. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection.
Ely LK; Green KJ; Beddoe T; Clements CS; Miles JJ; Bottomley SP; Zernich D; Kjer-Nielsen L; Purcell AW; McCluskey J; Rossjohn J; Burrows SR
J Immunol; 2005 May; 174(9):5593-601. PubMed ID: 15843558
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
3. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
Burrows SR; Khanna R; Burrows JM; Moss DJ
J Exp Med; 1994 Apr; 179(4):1155-61. PubMed ID: 7511682
[TBL] [Abstract][Full Text] [Related]
4. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity.
Burrows SR; Kienzle N; Winterhalter A; Bharadwaj M; Altman JD; Brooks A
J Immunol; 2000 Dec; 165(11):6229-34. PubMed ID: 11086057
[TBL] [Abstract][Full Text] [Related]
5. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen.
Burrows SR; Silins SL; Moss DJ; Khanna R; Misko IS; Argaet VP
J Exp Med; 1995 Dec; 182(6):1703-15. PubMed ID: 7500015
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire.
Burrows SR; Silins SL; Cross SM; Peh CA; Rischmueller M; Burrows JM; Elliott SL; McCluskey J
Eur J Immunol; 1997 Jan; 27(1):178-82. PubMed ID: 9022015
[TBL] [Abstract][Full Text] [Related]
7. The structure of HLA-B8 complexed to an immunodominant viral determinant: peptide-induced conformational changes and a mode of MHC class I dimerization.
Kjer-Nielsen L; Clements CS; Brooks AG; Purcell AW; Fontes MR; McCluskey J; Rossjohn J
J Immunol; 2002 Nov; 169(9):5153-60. PubMed ID: 12391232
[TBL] [Abstract][Full Text] [Related]
8. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
9. Direct alloreactivity by human cytotoxic T lymphocytes can Be inhibited by altered peptide ligand antagonism.
Burrows SR; Khanna R; Moss DJ
Blood; 1999 Feb; 93(3):1020-4. PubMed ID: 9920851
[TBL] [Abstract][Full Text] [Related]
10. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
11. An altered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I-associated neurological disease.
Kubota R; Soldan SS; Martin R; Jacobson S
J Immunol; 2000 May; 164(10):5192-8. PubMed ID: 10799878
[TBL] [Abstract][Full Text] [Related]
12. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines.
Crotzer VL; Christian RE; Brooks JM; Shabanowitz J; Settlage RE; Marto JA; White FM; Rickinson AB; Hunt DF; Engelhard VH
J Immunol; 2000 Jun; 164(12):6120-9. PubMed ID: 10843661
[TBL] [Abstract][Full Text] [Related]
13. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
[TBL] [Abstract][Full Text] [Related]
14. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
[TBL] [Abstract][Full Text] [Related]
15. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.
Elliott SL; Pye SJ; Schmidt C; Cross SM; Silins SL; Misko IS
J Infect Dis; 1997 Oct; 176(4):1068-72. PubMed ID: 9333169
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry.
Archbold JK; Macdonald WA; Miles JJ; Brennan RM; Kjer-Nielsen L; McCluskey J; Burrows SR; Rossjohn J
J Biol Chem; 2006 Nov; 281(45):34324-32. PubMed ID: 16963442
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315-324) epitope of human cytomegalovirus.
Prod'homme V; Retière C; Imbert-Marcille BM; Bonneville M; Hallet MM
J Immunol; 2003 Feb; 170(4):2030-6. PubMed ID: 12574373
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic peptides: a mechanism of cell type-specific immune escape.
Kummer M; Lev A; Reiter Y; Biedermann BC
J Immunol; 2005 Feb; 174(4):1947-53. PubMed ID: 15699122
[TBL] [Abstract][Full Text] [Related]
19. Allospecific T cell epitope sharing reveals extensive conservation of the antigenic features of peptide ligands among HLA-B27 subtypes differentially associated with spondyloarthritis.
Montserrat V; Martí M; López de Castro JA
J Immunol; 2003 Jun; 170(11):5778-85. PubMed ID: 12759462
[TBL] [Abstract][Full Text] [Related]
20. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.
Dutoit V; Rubio-Godoy V; Doucey MA; Batard P; Liénard D; Rimoldi D; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D
J Immunol; 2002 Feb; 168(3):1167-71. PubMed ID: 11801651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
